This study is testing a new drug called SL-325, which is a DR3 blocking antibody, in healthy volunteers. It's a first-in-human study, meaning it's one of the first times SL-325 is being given to people. The main goal is to check the safety and how well people tolerate SL-325, with measurements taken for about 75 days after the last dose. You might be able to join if you are between 18 and 55 years old, have a body mass index (BMI) between 18 and 32 kg/m2, weigh more than 50 kg, and have normal lab results. The study is currently recruiting about 72 participants.

Study design

This is a randomized, double-blind, placebo-controlled study, meaning some participants will receive SL-325 and others will receive a placebo (normal saline), and neither you nor the study staff will know which you are getting. It will involve about 72 healthy volunteers.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Your safety and tolerability will be measured from Day 1 through 75 days after your last dose.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.